Gastrointestinal Agents Market

Market Insights

Gastrointestinal (GI) symptoms generally include bloating, heartburn, indigestion or dyspepsia, and constipation. According to a new study, almost 74 percent of Americans suffer from digestive symptoms like gas, diarrhea, bloating, and abdominal pain. In this study’s scope, gastrointestinal disease or disorder includes gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).

Among the considered conditions, the incidence of GERD is the highest and most commonly observed, followed by IBS and IBD. Thus, the rise in chronic gastrointestinal disorders and diseases, along with the availability of OTC drugs, are driving the growth of the gastrointestinal drug market.

The report titled “Gastrointestinal Agents Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall gastrointestinal agents market, along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on types of drugs and different geographies.

The drug types studied for analyzing the overall global gastrointestinal agents market are majorly segmented into antidiarrheal, anti-ulcer, laxative, inflammatory bowel disease, and irritable bowel syndrome drugs.

Geographically, the global gastrointestinal agents market is studied for the following regional markets:

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global gastrointestinal agents market.

Tools such as market positioning of key players and appealing investment propositions provide readers with insights into the global gastrointestinal agents market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global gastrointestinal agents market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Based on the type of drug, the global gastrointestinal agents market is segmented as follows:

Antidiarrheal

• Anti-emetics
• Anticholinergic Agents
• Antihistamines
• Serotonin-5-HT3 Receptor Antagonists
• cannabinoid receptor antagonists

Anti-ulcers

• Histamine type 2 receptor blockers (H2 blockers)
• proton pump inhibitors
• Laxatives

Inflammatory bowel disease

• 5-Aminosalicylic Acid (5-ASA) Derivatives
• Immunosuppressive Agents
• Tumor Necrosis Factor Antagonists

Irritable bowel syndrome

• Antimuscarinics/Antispasmodics
• Prokinetic Agents

Medications for gastrointestinal diseases and symptoms include prescription and nonprescription drugs, conventional and unconventional agents, simple small molecules, complex macromolecules, and large recombinant proteins.

Because of the disease’s high prevalence in the region, inflammatory bowel disease held the largest share of the gastrointestinal agents market in 2016. While irritable bowel syndrome is anticipated to grow at the highest CAGR during the forecast period,

For the purpose of this study, the global gastrointestinal agents market is geographically categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

At present, North America dominates the global market for gastrointestinal agents. The United States, in particular, holds the largest market share in the regional gastrointestinal agents market. However, the region is expected to witness flat growth due to the maturity of this market and no anticipated competition from potential drugs.

Europe is considered to be the second-largest market for gastrointestinal agents. Asia Pacific is anticipated to be the fastest-growing market in the forecast period. The Asia Pacific market is being driven by rising gastrointestinal disease and disorder incidence, technological advancement, and overall improvement in healthcare infrastructure in emerging economies.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.2.1 Phase I – Secondary Research
1.2.2 Phase II – Primary Research
1.2.3 Phase III – Expert Panel Review
1.2.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Gastrointestinal Agents Market Portraiture
2.2 Global Gastrointestinal Agents Market Revenue, by Class, 2016 Vs 2025 (Value %)
2.3 Global Gastrointestinal Agents Market Revenue, by Geography, 2016 (US$ Million)

Chapter 3 Global Gastrointestinal Agents Market Analysis
3.1 Global Gastrointestinal Agents Market Overview
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Rise in the instances of gastrointestinal diseases and disorders
3.2.1.2 Active development in pipelines drugs and biologics
3.2.2 Challenges
3.2.2.1 Most of the patient prefers home remedies in its initial stage of diseases
3.2.3 Opportunities
3.2.3.1 Rise in used of OTC drugs and food supplements
3.3 Food Supplements as Supportive Therapy for Gastrointestinal Diseases (2015-2016) (US$)
3.4 Incidence Rate of GERD, IBD and IBS, 2016
3.5 Attractive Investment Proposition
3.6 Competitive Analysis: Key Players in Global Gastrointestinal Agents Market

Chapter 4 Gastrointestinal Agents Market Analysis, by Drug Class, 2015-2025 (US$ Mn)
4.1 Overview
4.2 Antidiarrheal
4.3 Anti-emetics
4.3.1 Anticholinergic Agents
4.3.2 Antihistamines
4.3.3 Serotonin 5-HT3 Receptor Antagonists
4.3.4 Cannabinoid Receptor Agonists
4.4 Anti-ulcers
4.4.1 Histamine type 2 receptor blockers (H2 blockers)
4.4.2 Proton Pump Inhibitors
4.5 Laxatives
4.6 Inflammatory bowel disease
4.6.1 5-Aminosalicyclic Acid (5-ASA) Derivatives
4.6.2 Immunosuppressive Agents
4.6.3 Tumor Necrosis Factor Antagonists
4.7 Irritable bowel syndrome
4.7.1 Antimuscarinics/Antispasmodics
4.7.2 Prokinetic Agents

Chapter 5 Americal Gastrointestinal Agents Market, by Geography, 2015-2025 (US$ Mn)
5.1 Overview
5.2 North Americ (USA and Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan, and Rest of Asia Pacific)
5.5 Latin America (Brazil, Mexico and Rest of Latin America)
5.6 Middle East and Africa (UAE, Saudi Arabia, South Africa and Rest of Middle East and Africa)

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Allergan Plc. (Formerly Actavis Plc.)
6.3 AstraZeneca
6.4 Bayer AG
6.5 Boehringer Ingelheim GmbH
6.6 GlaxoSmithKline plc.
6.7 Janssen Biotech, Inc.
6.8 Ranbaxy Laboratories Limited
6.9 Sanofi
6.10 Takeda Pharmaceutical
6.11 Valeant Pharmaceuticals, Inc.

List of Figures

FIG. 1 Global Gastrointestinal Agents Market: Research Methodology
FIG. 2 Global Gastrointestinal Agents Market Revenue, by Class, 2016 Vs 2025 (Value %)
FIG. 3 Global Gastrointestinal Agents Market Revenue, by Geography, 2016 (US$ Million)
FIG. 4 Attractive Investment Proposition: Global Gastrointestinal Agents Market
FIG. 5 Competitive Analysis: Key Players in Global Gastrointestinal Agents Market
FIG. 6 Antidiarrheal Market, 2015 – 2025 (US$ Mn)
FIG. 7 Anticholinergic Agents Market, 2015 – 2025 (US$ Mn)
FIG. 8 Antihistamine Agents Market, 2015 – 2025 (US$ Mn)
FIG. 9 Serotonin 5-HT3 Receptor Antagonists Market, 2015 – 2025 (US$ Mn)
FIG. 10 Cannabinoid Receptor Agonists Market, 2015 – 2025 (US$ Mn)
FIG. 11 Histamine Type 2 Receptor Blockers (H2 Blockers) Market, 2015 – 2025 (US$ Mn)
FIG. 12 Proton Pump Inhibitors Market, 2015 – 2025 (US$ Mn)
FIG. 13 Laxatives Market, 2015 – 2025 (US$ Mn)
FIG. 14 5-aminosalicylic Acid Derivatives Market, 2015 – 2025 (US$ Mn)
FIG. 15 Immunosuppressive Agents Market, 2015 – 2025 (US$ Mn)
FIG. 16 Tumor Necrosis Factor Antagonists Market, 2015 – 2025 (US$ Mn)
FIG. 17 Antimuscarinics/Antispasmodics Market, 2015 – 2025 (US$ Mn)
FIG. 18 Prokinetic Agents Market, 2015 – 2025 (US$ Mn)
FIG. 19 Latin America Gastrointestinal Agents, 2013 – 2024 (US$ Mn)
FIG. 20 Middle East & Africa Gastrointestinal Agents, 2013 – 2024 (US$ Mn)

List of Tables

TABLE 1 Food Supplements as Supportive Therapy for Gastrointestinal Diseases (2015-2016) (US$)
TABLE 2 Incidence rate of GERD, IBD and IBS, 2016
TABLE 3 Global Gastrointestinal Agents Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 4 Anti-emetics Global Gastrointestinal Agents Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 Anti-ulcers Global Gastrointestinal Agents Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 6 Global Inflammatory Bowel Disease Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 Global Irritable Bowel Disease Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 8 Global Gastrointestinal Agents Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 9 North America Gastrointestinal Agents Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 10 Europe Gastrointestinal Agents, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Asia Pacific Gastrointestinal Agents, by Country, 2013 – 2024 (US$ Mn)
TABLE 12 Abbott Laboratories: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Allergan Plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 AstraZeneca: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 Bayer AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 16 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Janssen Biotech, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Ranbaxy Laboratories Limited: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Sanofi: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 Takeda Pharmaceutical: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Valeant Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)